1. Home
  2. KNSA vs CNXN Comparison

KNSA vs CNXN Comparison

Compare KNSA & CNXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CNXN
  • Stock Information
  • Founded
  • KNSA 2015
  • CNXN 1982
  • Country
  • KNSA United Kingdom
  • CNXN United States
  • Employees
  • KNSA N/A
  • CNXN N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CNXN Catalog/Specialty Distribution
  • Sector
  • KNSA Health Care
  • CNXN Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • CNXN Nasdaq
  • Market Cap
  • KNSA 1.7B
  • CNXN 1.9B
  • IPO Year
  • KNSA 2018
  • CNXN 1998
  • Fundamental
  • Price
  • KNSA $20.59
  • CNXN $69.00
  • Analyst Decision
  • KNSA Strong Buy
  • CNXN
  • Analyst Count
  • KNSA 5
  • CNXN 0
  • Target Price
  • KNSA $36.60
  • CNXN N/A
  • AVG Volume (30 Days)
  • KNSA 290.2K
  • CNXN 81.1K
  • Earning Date
  • KNSA 10-29-2024
  • CNXN 02-12-2025
  • Dividend Yield
  • KNSA N/A
  • CNXN 0.58%
  • EPS Growth
  • KNSA N/A
  • CNXN 14.84
  • EPS
  • KNSA N/A
  • CNXN 3.40
  • Revenue
  • KNSA $384,098,000.00
  • CNXN $2,789,687,000.00
  • Revenue This Year
  • KNSA $60.05
  • CNXN $0.71
  • Revenue Next Year
  • KNSA $36.32
  • CNXN $5.15
  • P/E Ratio
  • KNSA N/A
  • CNXN $20.30
  • Revenue Growth
  • KNSA 54.41
  • CNXN N/A
  • 52 Week Low
  • KNSA $16.56
  • CNXN $57.47
  • 52 Week High
  • KNSA $28.15
  • CNXN $77.19
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 40.95
  • CNXN 37.90
  • Support Level
  • KNSA $19.97
  • CNXN $70.07
  • Resistance Level
  • KNSA $20.85
  • CNXN $75.08
  • Average True Range (ATR)
  • KNSA 0.69
  • CNXN 1.94
  • MACD
  • KNSA 0.03
  • CNXN -0.53
  • Stochastic Oscillator
  • KNSA 35.61
  • CNXN 2.22

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CNXN PC Connection Inc.

PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.

Share on Social Networks: